β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models*

Background: Accumulating evidence indicates that β receptors (βAR) may be involved in Alzheimer disease (AD) pathology and that amyloid β peptide (Aβ) may interact with β2AR independently of presynaptic activities. Results: β2AR, PKA, and JNK mediate Aβ-induced phosphorylation of tau in vivo and in vitro. Conclusion: An Aβ-β2AR signaling is involved in tau pathology in AD. Significance: This work indicates a potential mechanism for altering AD pathology by blocking β2ARs. Alzheimer disease (AD) is characterized by neurodegeneration marked by loss of synapses and spines associated with hyperphosphorylation of tau protein. Accumulating amyloid β peptide (Aβ) in brain is linked to neurofibrillary tangles composed of hyperphosphorylated tau in AD. Here, we identify β2-adrenergic receptor (β2AR) that mediates Aβ-induced tau pathology. In the prefrontal cortex (PFC) of 1-year-old transgenic mice with human familial mutant genes of presenilin 1 and amyloid precursor protein (PS1/APP), the phosphorylation of tau at Ser-214 Ser-262 and Thr-181, and the protein kinases including JNK, GSK3α/β, and Ca2+/calmodulin-dependent protein kinase II is increased significantly. Deletion of the β2AR gene in PS1/APP mice greatly decreases the phosphorylation of these proteins. Further analysis reveals that in primary PFC neurons, Aβ signals through a β2AR-PKA-JNK pathway, which is responsible for most of the phosphorylation of tau at Ser-214 and Ser-262 and a significant portion of phosphorylation at Thr-181. Aβ also induces a β2AR-dependent arrestin-ERK1/2 activity that does not participate in phosphorylation of tau. However, inhibition of the activity of MEK, an upstream enzyme of ERK1/2, partially blocks Aβ-induced tau phosphorylation at Thr-181. The density of dendritic spines and synapses is decreased in the deep layer of the PFC of 1-year-old PS1/APP mice, and the mice exhibit impairment of learning and memory in a novel object recognition paradigm. Deletion of the β2AR gene ameliorates pathological effects in these senile PS1/APP mice. The study indicates that β2AR may represent a potential therapeutic target for preventing the development of AD.

[1]  T. Kanno,et al.  Stimulation-Dependent Intraspinal Microtubules and Synaptic Failure in Alzheimer's Disease: A Review , 2012, International journal of Alzheimer's disease.

[2]  S. Kügler,et al.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. , 2011, The American journal of pathology.

[3]  Zhen Yan,et al.  Amyloid β Peptide-(1–42) Induces Internalization and Degradation of β2 Adrenergic Receptors in Prefrontal Cortical Neurons* , 2011, The Journal of Biological Chemistry.

[4]  L. Tan,et al.  Roles of β-adrenergic receptors in Alzheimer's disease: Implications for novel therapeutics , 2011, Brain Research Bulletin.

[5]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[6]  H. Kretzschmar,et al.  Multiple Events Lead to Dendritic Spine Loss in Triple Transgenic Alzheimer's Disease Mice , 2010, PloS one.

[7]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[8]  G. Govindaiah,et al.  Binding of amyloid β peptide to β2 adrenergic receptor induces PKA‐dependent AMPA receptor hyperactivity , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  S. Kügler,et al.  Modeling of Tau-Mediated Synaptic and Neuronal Degeneration in Alzheimer's Disease , 2010, International journal of Alzheimer's disease.

[10]  S. Nawoschik,et al.  The JNK pathway amplifies and drives subcellular changes in tau phosphorylation , 2009, Neuropharmacology.

[11]  S. Kügler,et al.  AAV-Tau Mediates Pyramidal Neurodegeneration by Cell-Cycle Re-Entry without Neurofibrillary Tangle Formation in Wild-Type Mice , 2009, PloS one.

[12]  F. Nicoletti,et al.  β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.

[13]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[14]  T. Kanno,et al.  Amyloid beta: a putative intra-spinal microtubule-depolymerizer to induce synapse-loss or dentritic spine shortening in Alzheimer's disease. , 2009, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

[15]  C. Lyketsos,et al.  Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[16]  M. Fleshner,et al.  Role of central β-adrenergic receptors in regulating proinflammatory cytokine responses to a peripheral bacterial challenge , 2008, Brain, Behavior, and Immunity.

[17]  Chun Guo,et al.  The β-Arrestin-2 Scaffold Protein Promotes c-Jun N-terminal Kinase-3 Activation by Binding to Its Nonconserved N Terminus* , 2008, Journal of Biological Chemistry.

[18]  L. Tan,et al.  Polymorphisms at the β2-adrenergic receptor gene influence Alzheimer's disease susceptibility , 2008, Brain Research.

[19]  Necmettin Yildirim,et al.  β2-Adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics* , 2008, Journal of Biological Chemistry.

[20]  T. Nabeshima,et al.  The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Ameliorates the Cognitive Dysfunction in Beta Amyloid25–35 I.c.v.-Injected Mice: Involvement of Dopaminergic Systems , 2007, Neuropsychopharmacology.

[21]  E. Mandelkow,et al.  Missorting of Tau in Neurons Causes Degeneration of Synapses That Can Be Rescued by the Kinase MARK2/Par-1 , 2007, The Journal of Neuroscience.

[22]  A. Arnsten,et al.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex. , 2007, Pharmacology & therapeutics.

[23]  Yun Bai,et al.  Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation , 2006, Nature Medicine.

[24]  W. G. Wood,et al.  Amyloid beta-protein1-42 increases cAMP and apolipoprotein E levels which are inhibited by β1 and β2-adrenergic receptor antagonists in mouse primary astrocytes , 2006, Neuroscience.

[25]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[26]  A. Cuello,et al.  Endogenous β-amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells , 2005, Neuroscience.

[27]  David A. Morilak,et al.  Role of brain norepinephrine in the behavioral response to stress , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[28]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[29]  T. Yamauchi,et al.  Phosphorylation of tau protein to sites found in Alzheimer's disease brain is catalyzed by Ca2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry , 2003, Neuroscience Letters.

[30]  D. Hochbaum,et al.  Activation of JNK by Epac Is Independent of Its Activity as a Rap Guanine Nucleotide Exchanger* , 2003, Journal of Biological Chemistry.

[31]  T. Nabeshima,et al.  Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  T. Hashikawa,et al.  Aberrant Tau Phosphorylation by Glycogen Synthase Kinase-3β and JNK3 Induces Oligomeric Tau Fibrils in COS-7 Cells* , 2002, The Journal of Biological Chemistry.

[33]  W. Hsu,et al.  G Protein and cAMP-Dependent Protein Kinase Mediate Amyloid β-Peptide Inhibition of Neuronal Glucose Uptake , 2001, Experimental Neurology.

[34]  G. Hall,et al.  Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease. , 2000, Journal of cell science.

[35]  M. Goedert,et al.  Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. , 1996, The Biochemical journal.

[36]  G. Johnson.  Differential Phosphorylation of τ by Cyclic AMP‐Dependent Protein Kinase and Ca2+/Calmodulin‐Dependent Protein Kinase II: Metabolic and Functional Consequences , 1992 .

[37]  G. Forloni,et al.  JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. , 2011, Journal of Alzheimer's disease : JAD.

[38]  G. Johnson.  Differential phosphorylation of tau by cyclic AMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase II: metabolic and functional consequences. , 1992, Journal of neurochemistry.